Phase 3, multicenter, multi-national, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of alfimeprase in subjects with occluded central venous access devices.

Trial Profile

Phase 3, multicenter, multi-national, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of alfimeprase in subjects with occluded central venous access devices.

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Jun 2011

At a glance

  • Drugs Alfimeprase (Primary)
  • Indications Catheter thrombosis; Peripheral arterial occlusive disorders
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SONOMA-2
  • Sponsors ARCA biopharma Inc
  • Most Recent Events

    • 17 Mar 2008 Nuvelo have decided to terminate their clinical development of alfimeprase after obtaining disappointing efficacy results in the SONOMA-3 trial [see media release 9086453 and profile 700018108].
    • 01 Jun 2007 Status changed from in progress to completed.
    • 23 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top